Acne Inversa Clinical Study (12 yrs+) |Austin TX & Phoenix AZ

A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa

Study Description

Brief Summary

The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa.

Condition or Disease

Hidradenitis Suppruativa

Study Design

Study Type:	Interventional (Clinical Trial)
Estimated Enrollment:	450
Primary Outcome Measures	1. Proportion of participants who achieve Hidradenitis Suppurativa (HS) Clinical Response 75 (HiSCR75) from baseline
Actual Study Start Date:	June 2025
Estimated Primary Completion Date:	October 2026

Eligibility Criteria

Ages Eligible for Study:	12 & Older
Sexes Eligible for Study:	All
Accepts Healthy Volunteers:	No

Study Population

Hidradenitis Supurativa

Inclusion Criteria

Diagnosis of HS for at least 6 months prior to screening visit
Mild to moderate HS (Hurley I or II) with the following at both screening and baseline visits: total AN count of at least 4, with no draining tunnels AND affecting at least 2 distinct anatomical areas
Agreement to NOT use topical and systemic antibiotics for treatment of HS during the vehicle-controlled period
Agreement to NOT use topical antiseptics, including washes and leave-on products on the areas affected by HS lesions during the vehicle-controlled period and Weeks 16 to 20 of the extension period

Exclusion Criteria

Body surface areas to be treated exceed 20% BSA at screening or baseline
Presence of draining tunnels at screening or baseline
Medical history including current or history of certain infections, cancer, lymphoproliferative disorders and other medical conditions at the discretion of the investigator
Laboratory values outside of the protocol-defined criteria
Pregnant or lactating participants, or those considering pregnancy during the period of their study participation

ADDITIONAL DETAILS

Application for Clinical Trials

This field is for validation purposes and should be left unchanged.

Name(Required)

First Name Last Name

Phone(Required)

Email(Required)

Birthday(Required)

Select a State(Required)

Select a Condition (Arizona)(Required)

Select a Condition (Kansas)(Required)

Select a Condition (Maryland)(Required)

Select a Condition (Missouri)(Required)

Select a Condition (Texas)(Required)

Select a Clinical Trial: Actinic Keratosis (Arizona)(Required)

Select a Clinical Trial: Alopecia Areata (Maryland)(Required)

Select a Clinical Trial: Atopic Dermatitis (Arizona)(Required)

Select a Clinical Trial: Atopic Dermatitis (Texas)(Required)

Select a Clinical Trial: Atopic Dermatitis (Maryland)(Required)

Select a Clinical Trial: Atopic Dermatitis (Missouri)(Required)

Select a Clinical Trial: Atopic Dermatitis (Kansas)(Required)

Select a Clinical Trial: Bullous Pemphigoid (Arizona)(Required)

Select a Clinical Trial: Hidradenitis Suppurativa (Arizona)(Required)

Select a Clinical Trial: Prurigo Nodularis (Arizona)(Required)

Select a Clinical Trial: Prurigo Nodularis (Maryland)(Required)

Select a Clinical Trial: Psoriasis (Arizona)(Required)

Select a Clinical Trial: Rosacea (Arizona)(Required)

Select a Clinical Trial: Psoriasis (Texas)(Required)

Select a Clinical Trial: Psoriasis (Maryland)(Required)

Select a Clinical Trial: Psoriasis (Missouri)(Required)

Select a Clinical Trial: Psoriasis (Kansas)(Required)

Select a Clinical Trial: Skincare (Arizona)(Required)

Select a Clinical Trial: Skin Cancer (Arizona)(Required)

Select a Clinical Trial: Skin Cancer (Missouri)(Required)

Select a Clinical Trial: Skin Cancer (Maryland)(Required)

Select a Clinical Trial: Vitiligo (Texas)(Required)

Select a Clinical Trial: Vitiligo (Missouri)(Required)

Select a Clinical Trial: Vitiligo (Kansas)(Required)

How did you hear about us?(Required)

Message(Required)

CAPTCHA

Menu

Hidradenitis Suppruativa Study (12 Years+)